According to research in The Lancet Respiratory Medicine, investigational antibody pamrevlumab reduced lung function decline and slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).

Fewer patients assigned pamrevlumab, as compared with placebo, experienced disease progression, defined as a decline in percentage of predicted FVC of 10% or more or death, at 48 weeks.

Pamrevlumab reduced the decline in percentage of predicted FVC by 60·3% at week 48 (mean change from baseline −2·9% with pamrevlumab vs −7·2% with placebo; between-group difference 4·3% [95% CI 0·4–8·3]; p=0·033).